Tags

Type your tag names separated by a space and hit enter

Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation.
Haematologica. 1999 Nov; 84(11):1007-11.H

Abstract

BACKGROUND AND OBJECTIVE

High-dose chemotherapy and autologous bone marrow transplantation (ABMT) has become the standard approach for most patients with relapsed or refractory Hodgkin's disease. Disease status at transplant has been correlated with outcome following ABMT. In light of this, we employ mini-BEAM (BCNU, etoposide, cytarabine and melphalan) salvage therapy in order to achieve a state of minimal residual disease prior to transplantation.

DESIGN AND METHODS

From February 1992 to June 1998 twenty-four patients receiving mini-BEAM therapy for resistance or relapse of their Hodgkin's disease were included. Four patients had obtained no response with initial chemotherapy (refractory), eight had obtained an incomplete response, seven were in first relapse and five in second or subsequent relapse. Fifteen patients received mini-BEAM as first salvage chemotherapy regimen. The remaining nine patients had previously been exposed to a median of one salvage regimen. Patients received a median of three cycles of mini-BEAM.

RESULTS

Sixteen patients achieved complete remission and four partial remission, yielding an overall response rate of 83%. No significant differences in response were observed between patients who received mini-BEAM as initial salvage therapy and those who had received a prior salvage regimen. Eighteen out of the twenty responding patients went on to intensive therapy and peripheral blood stem cell transplantation. With a median follow-up of 52 months, the cumulative probability of 7-year overall survival is 71% for the responders and that of the 6-year disease-free survival is 42%. No treatment-related deaths were observed.

INTERPRETATION AND CONCLUSIONS

Mini-BEAM is an effective salvage regimen with moderate toxicity that may be useful for cytoreduction prior to stem cell procedures.

Authors+Show Affiliations

Department of Hematology, Hospital La Paz, Universidad Autónoma de Madrid, Spain. fdezjnez@teleline.esNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

10553161

Citation

Fernández-Jiménez, M C., et al. "Salvage Chemotherapy With mini-BEAM for Relapsed or Refractory Hodgkin's Disease Prior to Autologous Peripheral Blood Stem Cell Transplantation." Haematologica, vol. 84, no. 11, 1999, pp. 1007-11.
Fernández-Jiménez MC, Canales MA, Ojeda E, et al. Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation. Haematologica. 1999;84(11):1007-11.
Fernández-Jiménez, M. C., Canales, M. A., Ojeda, E., de Bustos, J. G., Aguado, M. J., & Hernández-Navarro, F. (1999). Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation. Haematologica, 84(11), 1007-11.
Fernández-Jiménez MC, et al. Salvage Chemotherapy With mini-BEAM for Relapsed or Refractory Hodgkin's Disease Prior to Autologous Peripheral Blood Stem Cell Transplantation. Haematologica. 1999;84(11):1007-11. PubMed PMID: 10553161.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation. AU - Fernández-Jiménez,M C, AU - Canales,M A, AU - Ojeda,E, AU - de Bustos,J G, AU - Aguado,M J, AU - Hernández-Navarro,F, PY - 1999/12/20/pubmed PY - 1999/12/20/medline PY - 1999/12/20/entrez SP - 1007 EP - 11 JF - Haematologica JO - Haematologica VL - 84 IS - 11 N2 - BACKGROUND AND OBJECTIVE: High-dose chemotherapy and autologous bone marrow transplantation (ABMT) has become the standard approach for most patients with relapsed or refractory Hodgkin's disease. Disease status at transplant has been correlated with outcome following ABMT. In light of this, we employ mini-BEAM (BCNU, etoposide, cytarabine and melphalan) salvage therapy in order to achieve a state of minimal residual disease prior to transplantation. DESIGN AND METHODS: From February 1992 to June 1998 twenty-four patients receiving mini-BEAM therapy for resistance or relapse of their Hodgkin's disease were included. Four patients had obtained no response with initial chemotherapy (refractory), eight had obtained an incomplete response, seven were in first relapse and five in second or subsequent relapse. Fifteen patients received mini-BEAM as first salvage chemotherapy regimen. The remaining nine patients had previously been exposed to a median of one salvage regimen. Patients received a median of three cycles of mini-BEAM. RESULTS: Sixteen patients achieved complete remission and four partial remission, yielding an overall response rate of 83%. No significant differences in response were observed between patients who received mini-BEAM as initial salvage therapy and those who had received a prior salvage regimen. Eighteen out of the twenty responding patients went on to intensive therapy and peripheral blood stem cell transplantation. With a median follow-up of 52 months, the cumulative probability of 7-year overall survival is 71% for the responders and that of the 6-year disease-free survival is 42%. No treatment-related deaths were observed. INTERPRETATION AND CONCLUSIONS: Mini-BEAM is an effective salvage regimen with moderate toxicity that may be useful for cytoreduction prior to stem cell procedures. SN - 0390-6078 UR - https://www.unboundmedicine.com/medline/citation/10553161/Salvage_chemotherapy_with_mini_BEAM_for_relapsed_or_refractory_Hodgkin's_disease_prior_to_autologous_peripheral_blood_stem_cell_transplantation_ L2 - http://www.diseaseinfosearch.org/result/7171 DB - PRIME DP - Unbound Medicine ER -